Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The company’s pioneering research aims to develop and commercialize cancer therapeutics that target the DNA damage response (DDR) pathways. Aprea's lead product candidate, ATRN-119, is a macrocyclic ATR inhibitor designed for treating solid tumors with DDR-related gene mutations. This inhibitor is currently in a Phase 1/2a clinical trial and has shown promising preliminary data, being well tolerated with no dose-limiting toxicities.
Another key candidate, APR-1051, is a highly selective WEE1 kinase inhibitor. The company recently received FDA clearance for an Investigational New Drug (IND) application for APR-1051, enabling the initiation of a Phase 1 clinical trial aimed at treating cancers that overexpress Cyclin E, including ovarian and breast cancers. Preclinical studies have demonstrated APR-1051's potential low toxicity and high selectivity, making it a candidate for best-in-class treatment.
Aprea’s commitment to advancing precision oncology is underscored by recent financial results and corporate developments. For instance, as of March 31, 2024, the company reported $32.4 million in cash and cash equivalents. Notably, Aprea has secured a private placement financing of up to $34 million to support its ongoing and upcoming clinical trials. Furthermore, Aprea’s strong leadership team, including newly appointed Chief Medical Officer Dr. Nadeem Q. Mirza, continues to drive the company’s strategic initiatives.
Recent achievements include the presentation of promising preclinical and clinical data at major conferences such as the AACR Annual Meeting. These presentations highlighted the potential of ATRN-119 and APR-1051 in treating cancers with specific genetic mutations, reinforcing Aprea’s potential to fill significant unmet medical needs in oncology.
For more detailed information about Aprea Therapeutics and its innovative approaches to cancer treatment, please visit their website at www.aprea.com.
Aprea Therapeutics (Nasdaq: APRE) hosted a virtual R&D Day Webinar on October 30, 2020, featuring discussions by experts in hematology regarding clinical therapies for TP53 mutant MDS/AML patients. The agenda included a review of Aprea's Phase 3 clinical program and commercial strategies. Aprea's lead candidate, eprenetapopt, targets mutant tumor suppressor protein p53 and has received multiple FDA designations for MDS. The company is developing APR-548 as a next-generation agent with a planned Phase 1 trial. For more information, visit Aprea's website.
Aprea Therapeutics, Inc. (Nasdaq: APRE) has launched p53reactivation.com to enhance disease awareness regarding p53 mutations in cancer. This initiative aims to educate healthcare professionals on how these mutations are linked to poor treatment outcomes. With approximately half of all cancers featuring p53 mutations, the site seeks to promote understanding of diagnostic tests and potential targeted therapies, marking a significant step in addressing this unmet medical need.
Aprea Therapeutics (NASDAQ: APRE) announced FDA acceptance of its IND application for APR-548, targeting TP53 mutant myelodysplastic syndromes (MDS). This milestone is crucial for the next-generation small molecule aimed at reactivating mutant p53. CEO Christian S. Schade expressed optimism about initiating a Phase 1 clinical trial for APR-548, reinforcing Aprea's commitment to advancing therapeutic options for p53 mutated cancers. The company is also progressing with its lead product, eprenetapopt, which has received multiple FDA designations for MDS and other malignancies.
Aprea Therapeutics (NASDAQ: APRE) announced the addition of Michael A. Kelly to its Board of Directors, where he will be part of the audit and governance committees. With over 20 years in life sciences, Kelly has held senior roles at Amgen and founded Sentry Hill Partners. His expertise is expected to enhance Aprea's mutant p53 reactivator oncology programs aimed at commercialization. The company focuses on developing innovative cancer therapies, including APR-246, which has received several FDA designations for hematologic malignancies.
Aprea Therapeutics (NASDAQ: APRE) announced the appointment of Michael A. Kelly to its Board of Directors, who brings over 20 years of life sciences leadership. Kelly's experience includes senior roles at Amgen and his own consulting firm, Sentry Hill Partners. He will serve on the audit and governance committees. His financial and operational expertise is expected to bolster Aprea's efforts in advancing its mutant p53 reactivator oncology programs, particularly APR-246, which is in clinical development for various cancers.
Aprea Therapeutics (NASDAQ: APRE) announced the promotion of Gregory S. Wessels to Chief Commercial Officer. This move is timely as the company approaches significant milestones in its frontline MDS program and continues developing eprenetapopt. Wessels brings extensive oncology experience from Bristol-Myers Squibb. Additionally, independent directors Scott Rocklage, Ph.D., and Jonathan Hepple, Ph.D., will step down from the Board after nearly a decade. The company has received multiple FDA designations for eprenetapopt, its lead candidate targeting mutant p53, crucial for cancer therapy.
Aprea Therapeutics (NASDAQ: APRE) announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors, effective June 30, 2020. Dr. Namouni has over 20 years in oncology development, previously at Bristol-Myers Squibb, while Dr. Peters brings 25 years of experience from roles at Yumanity and Merrimack Pharmaceuticals. Their expertise is expected to bolster Aprea's mutant p53 reactivator oncology programs. Guido Magni, M.D., Ph.D. is stepping down from the Board. Aprea focuses on developing cancer therapeutics, particularly APR-246 for hematologic malignancies.
Aprea Therapeutics (Nasdaq: APRE) presented updated data from its Phase 1b/2 clinical trial of APR-246 combined with azacitidine for TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at the EHA Annual Meeting. The trial showed a 75% overall response rate (ORR) and a 57% complete remission (CR) rate in evaluable MDS patients. The median overall survival (OS) was 12.1 months across all patients and improved to 13.7 months for those receiving 3 or more cycles. The results indicate significant therapeutic potential for high-risk MDS and AML patients.
Aprea Therapeutics, Inc. (Nasdaq: APRE) has completed patient enrollment in its Phase 3 trial for eprenetapopt, a treatment targeting front-line TP53 mutant myelodysplastic syndromes (MDS). Topline results are anticipated by year-end 2020. The trial, involving 154 patients, compares eprenetapopt with azacitidine against azacitidine alone, focusing on the complete response rate. Aprea plans to submit applications for regulatory approvals in the U.S. and EU in 2021, bringing hope for a much-needed therapy for patients suffering from TP53 mutated MDS.
Aprea Therapeutics (APRE) reported its Q1 2020 financial results on May 15, 2020, showcasing a net loss of $9.4 million, or $0.45 per share, compared to a loss of $3.5 million, or $2.97 per share in Q1 2019. The company's cash and cash equivalents totaled $122.5 million, sufficient to support operations through 2023. Despite challenges from COVID-19, patient enrollment in clinical trials for its lead compound, eprenetapopt, is improving. Aprea has received FDA Breakthrough Therapy Designation for eprenetapopt in combination with azacitidine for MDS treatment.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
What is Aprea Therapeutics' main focus?
What are Aprea Therapeutics' lead product candidates?
What is the current status of ATRN-119?
What recent achievement is related to APR-1051?
How is Aprea Therapeutics funded for its clinical trials?
Who is the newly appointed Chief Medical Officer at Aprea Therapeutics?
What significant events did Aprea participate in recently?
What are some unique attributes of ATRN-119?
What is Aprea's approach to addressing unmet medical needs in oncology?
Where can I find more information about Aprea Therapeutics?
